Men's Health News

RSS

Research suggests that IMRT may not be more effective in patients who had prostatectomy

Intensity-modulated radiation therapy has become the most commonly used type of radiation in prostate cancer, but research from the University of North Carolina suggests that the therapy may not be more effective than older, less expensive forms of radiation therapy in patients who have had a prostatectomy.

22 May 2013

Findings suggest that a prosaposin-based drug could block metastasis spread

By studying the roles two proteins, thrombospondin-1 and prosaposin, play in discouraging cancer metastasis, a trans-Atlantic research team has identified a five-amino acid fragment of prosaposin that significantly reduces metastatic spread in mouse models of prostate, breast and lung cancer.

22 May 2013

No significant benefit differences between IMRT and CRT therapies after prostatectomy

Use of the newer, more expensive intensity-modulated radiotherapy (IMRT) and use of the older conformal radiotherapy (CRT) after surgical removal of all or part of the prostate gland were associated with similar morbidity and cancer control outcomes, according to a study published Online First by JAMA Internal Medicine, a JAMA Network publication.

21 May 2013

UCLA study: Older men with multiple underlying health problems should avoid prostate cancer treatment

Older prostate cancer patients with other underlying health conditions should think twice before committing to surgery or radiation therapy for their cancer, according to a multicenter study led by researchers in the UCLA Department of Urology.

21 May 2013

Article examines global health policies and burden of disease on men

Men experience a higher burden of disease and lower life expectancy than women, but policies focusing on the health needs of men are notably absent from the strategies of global health organisations, according to a Viewpoint article in this week's Lancet.

18 May 2013

Regularly taking prescription painkillers is associated with higher risk of ED in men

Regularly taking prescription painkillers, also known as opioids, is associated with a higher risk of erectile dysfunction (ED) in men, according to a study published online today in the journal Spine.

17 May 2013

Cedars-Sinai launches new clinical trial to study effects of cabozantinib in prostate cancer patients

Researchers at Cedars-Sinai have launched a new clinical trial to investigate the effects of a cancer-fighting drug therapy that has shown favorable outcomes in patients with advanced metastatic prostate cancer.

17 May 2013

PCF funds two new Young Investigators in China to lead research projects on prostate cancer

The Prostate Cancer Foundation today announced that it is funding two more Young Investigators in China to lead innovative research projects within the country and expand PCF's global knowledge exchange on game-changing research in prostate cancer.

17 May 2013

Bayer HealthCare to present new data on oncology portfolio at ASCO meeting

Bayer HealthCare announced today that new data on the oncology portfolio, including Nexavar (sorafenib) tablets, Stivarga (regorafenib) tablets and the recently U.S. Food and Drug Administration approved product Xofigo (radium Ra 223 dichloride) injection will be presented at the 49th Annual Meeting of the American Society of Clinical Oncology, May 31 – June 4, in Chicago, IL (USA).

16 May 2013

Researchers explain why cost of care higher for men with severe psoriasis

Men often suffer from more severe cases of psoriasis than women, which may explain why the cost of care for men is higher. This is the conclusion of researchers at Umeå University in a new study.

16 May 2013

Study underscores new paradigm in cancer therapy

In the largest clinical trial to date to examine the efficacy of PARP inhibitor therapy in BRCA 1/2 carriers with diseases other than breast and ovarian cancer, the oral drug olaparib was found to be effective against advanced pancreatic and prostate cancers.

16 May 2013

Finding targets prostate patients who would not benefit from cancer-detecting biopsy

UC Irvine Health urologists and health policy experts report in a new study that two written assessments that identify existing comorbidities - the patient-reported Total Illness Burden Index for Prostate Cancer (TIBI-Cap) and the physician-reported Charlson Comorbidity Index - can successfully target prostate patients who would not benefit from biopsy to discover possible cancer.

16 May 2013

Prostate cancer drug Xofigo gets FDA approval

The U.S. Food and Drug Administration today approved Xofigo (radium Ra 223 dichloride) to treat men with symptomatic late-stage (metastatic) castration-resistant prostate cancer that has spread to bones but not to other organs.

16 May 2013

Competing in sport coalitions can raise testosterone levels in males, says MU professor

Sporting events can bring a community together, such as when the Louisville Cardinals won the NCAA championship and University of Louisville campus was filled with camaraderie.

15 May 2013

Prostate cancer patients need to be aware of the effects of androgen deprivation therapy

Androgen deprivation therapy is a common and effective treatment for advanced prostate cancer. However, among other side-effects, it can cause significant bone thinning in men on long-term treatment.

15 May 2013

Biogen Idec announces FDA's acceptance of ELOCTATE BLA for treatment of hemophilia A

Biogen Idec announced today that the U.S. Food and Drug Administration has accepted the company's Biologics License Application for the marketing approval of ELOCTATE (recombinant factor VIII Fc fusion protein) for the treatment of hemophilia A.

13 May 2013

Exposure to Agent Orange may increase risk of developing lethal forms of prostate cancer

A new analysis has found a link between exposure to Agent Orange and lethal forms of prostate cancer among US Veterans. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the findings suggest that Agent Orange exposure history should be incorporated into prostate screening decisions for Veterans.

13 May 2013

Men's Health News

Research suggests that IMRT may not be more effective in patients who had prostatectomy

Findings suggest that a prosaposin-based drug could block metastasis spread

No significant benefit differences between IMRT and CRT therapies after prostatectomy

UCLA study: Older men with multiple underlying health problems should avoid prostate cancer treatment

Article examines global health policies and burden of disease on men

Regularly taking prescription painkillers is associated with higher risk of ED in men

Cedars-Sinai launches new clinical trial to study effects of cabozantinib in prostate cancer patients

PCF funds two new Young Investigators in China to lead research projects on prostate cancer

Bayer HealthCare to present new data on oncology portfolio at ASCO meeting

Researchers explain why cost of care higher for men with severe psoriasis

Study underscores new paradigm in cancer therapy

Finding targets prostate patients who would not benefit from cancer-detecting biopsy

Prostate cancer drug Xofigo gets FDA approval

Competing in sport coalitions can raise testosterone levels in males, says MU professor

Prostate cancer patients need to be aware of the effects of androgen deprivation therapy

Biogen Idec announces FDA's acceptance of ELOCTATE BLA for treatment of hemophilia A

Exposure to Agent Orange may increase risk of developing lethal forms of prostate cancer

UNM Cancer Center to participate in Phase 3 clinical trial of novel treatment for men with prostate cancer

New study identifies four genetic variants associated with increased risk of testicular cancer

Men are more likely to engage in purging at high levels of sexual harassment

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News